FDA Commissioner nominee Scott Gottlieb will recuse himself for one year from decisions relating to more than 20 companies, including large device makers, according to his ethics disclosure form.
Gottlieb, whose nomination hearing is scheduled for April 5, plans to resign from 13 industry roles upon being confirmed and will divest his company stock and other financial interests.
Gottlieb plans to resign from board positions at GlaxoSmithKline and Daiichi Sankyo, and will also recuse himself from dealings concerning Bristol-Myers Squibb, for a one-year period following participation in a consulting project. He had previously resigned from positions at Tivorsan Pharmaceuticals, Gradalis and Strike Bio, but will still recuse himself for the next year.
He will also resign from jobs at the venture capital firm New Enterprise Associates, as well as at T.R. Winston & Co., a banking firm.